Novacap becomes Seqens!


SEQENS: a new name for a global leader in pharmaceutical synthesis and specialty ingredients

Novacap and all its activities unify their names into a new one and become SEQENS.

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.

SEQENS operates 24 manufacturing plants and 3 R&D centers in Europe, North America and Asia with 3,200 employees. More than 300 scientists, engineers and experts develop tailor-made solutions for our customers and ensure that products are successfully transferred into production.

Taking science to next level

SEQENS refers naturally to our core synthesis activities, mixed with that sequencing idea in which we arrange molecules, competencies and technologies to take science to the next level. In the pharmaceutical industry, SEQENS supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products. SEQENS also develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

The Continuum of Progress

As SEQENS, we intend to stand as a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our mission is to bring R&D and industrial performance to our clients’ projects.

From now on, we want to better leverage on our strong expertise to develop and produce highly complex molecules with unique skills and the largest continuum of technologies available on the market. I am proud of what we have achieved so far, on behalf of SEQENS’ 3,200 scientists, engineers, and experts working across a range of fields such as QHSE, industrial methods and processes, quality, sales and marketing, finance, innovation, legal and more.

Pierre Luzeau